Eqis Capital Management, Inc. Immuno Gen, Inc. Transaction History

Eqis Capital Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $4,695 - $6,511	-1,032 Reduced 5.26%	18,605 $92,000
Q3 2022 Oct 24, 2022	SELL	$4.48 - $6.47 $3,727 - $5,383	-832 Reduced 4.06%	19,637 $93,000
Q2 2022 Aug 08, 2022	BUY	$3.15 - $5.76 $1,083 - $1,981	344 Added 1.71%	20,469 $92,000
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $85,732 - $150,535	20,125 New	20,125 $96,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.